{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066420","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.393682+00:00","generated_at":"2026-05-22T03:55:08.063612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcadia Biosciences Q1 net income $2.6M; Zola sales up 90%; Roosevelt deal amended to 90/10 split","bullets":["Q1 2025 net income $2.6M ($1.90/share) vs net loss of $2.4M ($1.78 loss) in Q1 2024.","Revenue $1.2M (+22% YoY) driven by Zola coconut water sales up 90% and distribution up 70%.","Sold patent portfolios for $750K, eliminating $1M in liabilities; operating expenses near 10-year low.","Amended Roosevelt merger: fixed equity split 90% to Roosevelt partners, 10% to Arcadia stockholders; expected close late summer.","Cash and cash equivalents $3.16M, down from $4.24M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066420","json":"https://secwatch.observer/filing/0000950170-25-066420.json","markdown":"https://secwatch.observer/filing/0000950170-25-066420.md","text":"https://secwatch.observer/filing/0000950170-25-066420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017025066420/0000950170-25-066420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017025066420/rkda-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:55:08.063612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}